Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease

Time to Composite Clinical Outcome of a Sustained Decline of >=30 Percent (%) in eGFR, the Onset of end-stage Kidney Disease or Death

Time frame: From Baseline Through Study Completion (Approximately 2 Years After the Last Participant Enrolls)

Safety and Tolerability as Assessed by Number of Participants With Adverse events (AEs) and Serious Adverse Events (SAEs)

Time frame: Day 1 Through Study Completion (Approximately 2 Years After the Last Participant Enrolls)

Maximum Plasma Concentration (Cmax) of VX-147

Time frame: Day 1 and Week 40

Area Under the Concentration Versus Time Curve During a Dosing Interval (AUCtau) of VX-147

Time frame: Day 1 and Week 40

Observed Pre-dose Plasma Concentration (Ctrough) of VX-147

Time frame: Day 1 up to Week 40

Acceptability Tablet Formulation of VX-147 in Pediatric Participants using the Convenience Domain of the Treatment Satisfaction Questionnaire for Medication (TSQM) Version 1.4